ATR抑制剂VX-970联合标准治疗改善食管癌疗效的临床前测试
食管癌5年生存率持续偏低,被英国癌症研究中心列为未满足需求的癌症。本研究在食管癌细胞系中评估ATR抑制剂VX-970联合顺铂、卡铂及放疗的疗效,体外实验显示联合治疗增加肿瘤细胞杀伤,体内实验观察到VX-970联合放疗显著延迟肿瘤生长。结论认为VX-970是有效化疗/放疗增敏剂,可融入当前治疗范式,计划开展I期剂量递增安全性研究。
要点
- VX-970联合顺铂、卡铂或放疗在体外增加食管癌细胞杀伤。
- 体内实验中VX-970联合放疗显著延迟肿瘤生长。
- 计划开展VX-970联合放化疗的I期剂量递增安全性研究。
核心结论
- VX-970是有效的化疗/放疗增敏剂,可融入当前食管癌治疗范式以改善治疗反应。
研究设计与样本
- 使用食管癌细胞系进行体外和体内临床前研究,评估VX-970联合顺铂、卡铂及放疗的疗效。
- 放疗实验在模拟肿瘤微环境的缺氧条件下进行。
主要发现
- VX-970联合顺铂、卡铂和放疗在体外增加肿瘤细胞杀伤。
- VX-970联合放疗在体内观察到显著的肿瘤生长延迟。
临床怎么用
- VX-970可作为化疗/放疗增敏剂融入当前食管癌治疗范式。
- 计划在前瞻性I期剂量递增安全性研究中测试VX-970联合放化疗(EudraCT号:2015-003965-27)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Esophageal cancer has a persistently low 5-year survival rate and has recently been classified as a cancer of unmet need by Cancer Research UK. Consequently, new approaches to therapy are urgently required. Here, we tested the hypothesis that an ATR inhibitor, VX-970, used in combination with standard therapies for esophageal cancer could improve treatment outcome. MATERIAL AND METHODS: Using esophageal cancer cell lines we evaluated the efficacy of combining VX-970 with cisplatin and carboplatin in vitro and with radiation in vitro and in vivo. Radiation experiments were also carried out in hypoxic conditions to mimic the tumor microenvironment. RESULTS: Combining VX-970 with cisplatin, carboplatin and radiation increased tumor cell kill in vitro. A significant tumor growth delay was observed when VX-970 was combined with radiotherapy in vivo. CONCLUSIONS: VX-970 is an effective chemo/radiosensitizer which could be readily integrated in the current treatment paradigm to improve the treatment response in esophageal cancer and we plan to test it prospectively in the forthcoming phase I dose escalation safety study combining the ATR inhibitor VX-970 with chemoradiotherapy in esophageal cancer (EudraCT number: 2015-003965-27).
引用
- Leszczynska KB, Dobrynin G, Leslie RE, et al. Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer. Radiother Oncol. 2016. PMID: 27839769. doi:10.1016/j.radonc.2016.10.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。